Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRNS Barinthus Biotherapeutics	$1.19 +0.4%	$1.21	$0.64 ▼ $2.92	$48.46M	-0.73	52,968 shs	6,823 shs
CYCC Cyclacel Pharmaceuticals	$7.99 -0.1%	$7.80	$3.08 ▼ $597.60	$17.90M	0.08	227,439 shs	42,660 shs
LTRN Lantern Pharma	$4.51 +7.6%	$3.94	$2.55 ▼ $6.12	$48.71M	1.6	166,952 shs	67,765 shs
NRXP NRx Pharmaceuticals	$2.64 +4.3%	$2.98	$1.10 ▼ $6.01	$52.30M	1.59	382,720 shs	696,329 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRNS Barinthus Biotherapeutics	0.00%	-5.18%	-33.52%	+81.96%	0.00%
CYCC Cyclacel Pharmaceuticals	0.00%	+0.50%	-50.19%	-63.26%	-97.27%
LTRN Lantern Pharma	0.00%	-1.31%	+6.37%	+37.08%	-3.01%
NRXP NRx Pharmaceuticals	0.00%	-8.65%	-12.00%	+0.76%	+26.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BRNS Barinthus Biotherapeutics	2.9844 of 5 stars	3.5	3.0	3.6	0.0	1.3
CYCC Cyclacel Pharmaceuticals	0.4903 of 5 stars	0.0	4.0	0.0	2.5	0.0
LTRN Lantern Pharma	2.6462 of 5 stars	3.5	3.0	2.9	0.8	0.6
NRXP NRx Pharmaceuticals	3.0924 of 5 stars	3.6	5.0	2.2	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BRNS Barinthus Biotherapeutics	3.00	Buy	$3.00	152.10% Upside
CYCC Cyclacel Pharmaceuticals	2.00	Hold	N/A	N/A
LTRN Lantern Pharma	3.00	Buy	$25.00	454.32% Upside
NRXP NRx Pharmaceuticals	3.20	Buy	$28.50	979.55% Upside

Current Analyst Ratings Breakdown

Latest CYCC, BRNS, NRXP, and LTRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
8/11/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
8/4/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
6/20/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
6/6/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BRNS Barinthus Biotherapeutics	$14.97M	3.24	N/A	N/A	$3.23 per share	0.37
CYCC Cyclacel Pharmaceuticals	$40K	447.44	N/A	N/A	($58.87) per share	-0.14
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	$1.96 per share	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	($1.48) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BRNS Barinthus Biotherapeutics	-$61.07M	-$1.73	N/A	N/A	N/A	N/A	-54.70%	-44.75%	11/5/2025 (Estimated)
CYCC Cyclacel Pharmaceuticals	-$11.21M	-$839.58	N/A	∞	N/A	N/A	-723.64%	-145.51%	11/10/2025 (Estimated)
LTRN Lantern Pharma	-$20.78M	-$1.78	N/A	N/A	N/A	N/A	-99.89%	-81.58%	11/6/2025 (Estimated)
NRXP NRx Pharmaceuticals	-$25.13M	-$2.24	N/A	N/A	N/A	N/A	N/A	-550.94%	11/13/2025 (Estimated)

Latest CYCC, BRNS, NRXP, and LTRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2025	Q2 2025	NRXP NRx Pharmaceuticals	-$0.31	-$0.98	-$0.67	-$0.98	N/A	N/A
8/13/2025	Q2 2025	CYCC Cyclacel Pharmaceuticals	-$72.00	-$0.98	+$71.02	-$0.98	$0.03 million	N/A
8/13/2025	Q2 2025	LTRN Lantern Pharma	-$0.53	-$0.40	+$0.13	-$0.40	N/A	N/A
8/7/2025	Q2 2025	BRNS Barinthus Biotherapeutics	-$0.29	-$0.52	-$0.23	-$0.52	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
CYCC Cyclacel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BRNS Barinthus Biotherapeutics	N/A	7.89	7.89
CYCC Cyclacel Pharmaceuticals	N/A	5.77	5.77
LTRN Lantern Pharma	N/A	3.52	3.52
NRXP NRx Pharmaceuticals	N/A	0.11	0.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BRNS Barinthus Biotherapeutics	25.20%
CYCC Cyclacel Pharmaceuticals	23.58%
LTRN Lantern Pharma	28.62%
NRXP NRx Pharmaceuticals	4.27%

Insider Ownership

Company	Insider Ownership
BRNS Barinthus Biotherapeutics	8.00%
CYCC Cyclacel Pharmaceuticals	51.20%
LTRN Lantern Pharma	8.50%
NRXP NRx Pharmaceuticals	19.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BRNS Barinthus Biotherapeutics	107	40.72 million	37.46 million	N/A
CYCC Cyclacel Pharmaceuticals	14	2.24 million	1.09 million	Optionable
LTRN Lantern Pharma	20	10.80 million	9.88 million	Optionable
NRXP NRx Pharmaceuticals	2	19.81 million	16.05 million	Optionable

CYCC, BRNS, NRXP, and LTRN Headlines

Recent News About These Companies

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q2 2025 Earnings Call Transcript

August 21, 2025 | msn.com

NRx Pharmaceuticals, Inc. (NRXP) Q2 2025 Earnings Call Transcript

August 20, 2025 | seekingalpha.com

NRx Pharmaceuticals (NASDAQ:NRXP) Given Buy Rating at D. Boral Capital

August 20, 2025 | americanbankingnews.com

Advancements on Multiple Fronts in $3 Billion Suicidal Depression Market, Highlighted by FDA Fast Track Designation for Effective NRX 100 Drug Therapy: NRx Pharmaceuticals, Inc ...

August 19, 2025 | theglobeandmail.com

NRx Pharmaceuticals (NASDAQ: NRXP) Reports Q2 2025 Results, Highlights Progress Across Lead Programs

August 19, 2025 | msn.com

Nrx Pharmaceuticals Faces Financing Hurdles in Strategic Acquisitions of Kadima and Dura Medical

August 19, 2025 | msn.com

NRX Pharmaceuticals Inc (NRXP) Q2 2025 Earnings Report Preview: What to Expect

August 19, 2025 | finance.yahoo.com

NRx Pharmaceuticals sees cash runway into 2026

August 18, 2025 | msn.com

What To Expect From NRX Pharmaceuticals Inc (NRXP) Q2 2025 Earnings

August 18, 2025 | finance.yahoo.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and ...

August 18, 2025 | gurufocus.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and ...

August 18, 2025 | gurufocus.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 18, 2025 | globenewswire.com

NRX Pharmaceuticals Gains FDA Fast Track for NRX-100

August 16, 2025 | msn.com

Insights Ahead: NRX Pharmaceuticals's Quarterly Earnings

August 14, 2025 | benzinga.com

NRx Pharmaceuticals' (NRXP) "Buy" Rating Reiterated at D. Boral Capital

August 14, 2025 | americanbankingnews.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results ...

August 13, 2025 | gurufocus.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025

August 13, 2025 | prnewswire.com

NRx Pharmaceuticals to Report Q2 2025 Results on August 14

August 13, 2025 | msn.com

New to The Street Client NRx Pharmaceuticals (NASDAQ:NRXP) Secures FDA Fast Track Designation for NRX-100, Expanding Reach to 13 Million Americans Confronting Suicidal Ideation

August 12, 2025 | miamiherald.comM

New to The Street Client NRx Pharmaceuticals Secures FDA Fast Track Designation for NRX-100, Expanding Reach to 13 Million Americans Confronting Suicidal Ideation

August 11, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYCC, BRNS, NRXP, and LTRN Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

$1.19 +0.01 (+0.42%)

Closing price 08/22/2025 03:50 PM Eastern

Extended Trading

$1.21 +0.02 (+1.68%)

As of 08/22/2025 04:54 PM Eastern

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Cyclacel Pharmaceuticals NASDAQ:CYCC

$7.99 -0.01 (-0.13%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$8.03 +0.04 (+0.50%)

As of 08/22/2025 07:48 PM Eastern

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Lantern Pharma NASDAQ:LTRN

$4.51 +0.32 (+7.64%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.39 -0.12 (-2.64%)

As of 08/22/2025 07:56 PM Eastern

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

NRx Pharmaceuticals NASDAQ:NRXP

$2.64 +0.11 (+4.35%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.71 +0.07 (+2.65%)

As of 08/22/2025 07:58 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time